Q32 Bio (NASDAQ:QTTB) CFO Sells $65,776.32 in Stock

Posted by Francis Steltz on Aug 27th, 2026

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) CFO Lee Kalowski sold 3,972 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $65,776.32. Following the completion of the sale, the chief financial officer directly owned 138,471 shares in the company, valued at $2,293,079.76. This trade represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Q32 Bio Stock Down 0.2%

Shares of QTTB stock traded down $0.03 on Thursday, hitting $16.15. The company had a trading volume of 198,925 shares, compared to its average volume of 745,675. Q32 Bio Inc. has a twelve month low of $1.62 and a twelve month high of $23.57. The firm has a market cap of $480.77 million, a P/E ratio of 5.38 and a beta of 0.23. The company has a 50-day moving average price of $14.75 and a 200-day moving average price of $9.59.

Q32 Bio (NASDAQ:QTTB – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.02. Equities research analysts expect that Q32 Bio Inc. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Q32 Bio from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 21st. Mizuho assumed coverage on Q32 Bio in a research report on Friday, May 22nd. They set an “outperform” rating and a $14.00 target price on the stock. Oppenheimer lifted their price target on Q32 Bio from $20.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Cantor Fitzgerald assumed coverage on Q32 Bio in a report on Monday, May 18th. They issued an “overweight” rating for the company. Finally, HC Wainwright increased their price target on Q32 Bio from $13.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.00.

Check Out Our Latest Analysis on Q32 Bio

Hedge Funds Weigh In On Q32 Bio

A number of large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new position in Q32 Bio during the first quarter valued at $68,000. Goldman Sachs Group Inc. increased its stake in shares of Q32 Bio by 140.9% during the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after purchasing an additional 25,953 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Q32 Bio during the first quarter worth about $50,000. Marshall Wace LLP acquired a new position in shares of Q32 Bio during the 2nd quarter worth about $25,000. Finally, Jane Street Group LLC purchased a new position in Q32 Bio in the 2nd quarter valued at about $69,000. 31.32% of the stock is currently owned by institutional investors and hedge funds.

Q32 Bio Company Profile

(Get Free Report)

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.